Physician profile
Richard Matter
NPI 1073573481
$998.39
in general payments reported to CMS, 2019-2025
26 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $43.82 · 2022: $36.41 · 2023: $162 · 2024: $339 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $140.35 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Regeneron Healthcare Solutions, INC. | $109.41 | 2019-2025 | Libtayo, Lynozyfic |
| Janssen Biotech, INC. | $108.94 | 2022-2024 | Imbruvica, Darzalex, Talvey |
| Astrazeneca Pharmaceuticals LP | $83.78 | 2019-2024 | Tagrisso |
| Incyte Corporation | $78.29 | 2019-2024 | Jakafi |
| Eisai INC. | $47.80 | 2019-2024 | |
| Stemline Therapeutics INC. | $36.64 | 2025 | Orserdu |
| Clovis Oncology, INC. | $35.61 | 2019-2020 | |
| Amgen INC. | $30.47 | 2020-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $28.94 | 2019-2020 | |
| Progenics Pharmaceuticals, INC. | $28.65 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.22 | 2025 | Fruzaqla |
| Rigel Pharmaceuticals, INC. | $22.81 | 2019 | |
| Abbvie INC. | $22.59 | 2024 | |
| Celgene Corporation | $21.90 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $21.66 | 2023 | Poteligeo |
| Karyopharm Therapeutics INC. | $21.22 | 2024 | Xpovio |
| Pharmacosmos Therapeutics INC. | $19.78 | 2024 | Monoferric |
| Novartis Pharmaceuticals Corporation | $18.85 | 2025 | |
| G1 Therapeutics, INC. | $15.77 | 2023 | Cosela |
| Advanced Accelerator Applications | $15.12 | 2019 | |
| Lilly USA, LLC | $14.50 | 2019 | |
| Genentech USA, INC. | $14.47 | 2024 | Venclexta |
| Astellas Pharma US INC | $14.02 | 2024 | Xtandi |
| Amag Pharmaceuticals, INC. | $12.27 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Matter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.